Twenty-eight anal carcinomas were analyzed for their proliferative status and immunoreactivity to epidermal growth factor receptor (EGFR), HER2/neu, and proliferating cell nuclear antigen (PCNA). EGFR was expressed in 97.3% of tumors. Strong EGFR immunoreactivity correlated with a high proliferative rate (p=0.0 14). No obvious relationship existed between HER2/neu immunoreactivity and proliferative rate. The strong correlation between strong EGFR immunoreactivity and tumor proliferation suggests that the EGFR may represent a therapeutic target in anal cancers.
1. Velu TJ. Structure, function and transforming potential of the epidermal growth factor receptor. Mol Cell Endocrinol70:205-216, 1990
2.
2. Sporn MB, Roberts A.The epidermal growth factor family. In Sporn MB, Roberts AN (eds). Peptide growth factors and their receptors. Springer-Verlag, Berlin, pp. 100-367, 1990
3.
3. Bargmann CI, Hung M-C, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature319:226-230, 1986
4.
4. Hopenreijs VPT, Pels E, Vrensen GFJM, Oosting J, Treffers WF. Effects of human epidermal growth factor on endothelial wound healing of human corneas. Invest Ophthalmol Vis Sci33:1946-1957, 1992
5.
5. Lau AR, Kanemitsu MY, Kurata WE, Danesh S, Boynton AL. Epidermal growth factor disrupts gap-junctional communication and induces phosphorylation of connexin43 on serine. Mol Biol Cell3:865-874, 1992
6.
6. Buhrow SA, Cohen S, Staros JV. Affinity labeling of the protein kinase associated with epidermal growth factor receptor in membrane vesicles. J Biol Chem257:4019-4022, 1982
7.
7. Arfiles A, Kraft N, Ootaka T, Hutchinson P, Atkins RC. Epidermal growth factor and transforming growth factor-alpha stimulate or inhibit proliferation of a human renal adenocarcinoma cell line depending on cell status. Differentiation of the 2 pathways by G protein involvement. Cancer Res52:4356-4360, 1992
8.
8. Burgess AW. Epidermal growth factor and transforming growth factors. Br Med Bull45:101-124, 1989
9.
9. Yarden Y, Schlessinger J.Self phosphorylation of epidermal growth factor receptor: Evidence for a model of intermolecular allosteric activation. Biochemistry26:1434-1442, 1987
10.
10. Yarden Y, Schlessinger J.Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry26:1434-1442, 1987
11.
11. Carpenter G.Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem56:881-914, 1987
12.
12. Ellis C, Moran M, McCormick F, Pawson T.Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature. London343:377-381, 1990
13.
13. den Hartig JC, van Bergen EN, Henegouwen PMP, Verkley AJ, Boonstra J.The EGFR is an actin-binding protein. J Cell Biol119:349-355, 1992
14.
14. Wiegant FAC, Blok FJ, Defize LHK, Linnemans WAM, Verkley AJ, Boonstra J.Epidermal growth factor receptors associated to cytoskeletal elements of epidermoid carcinoma (A431) cells. J Cell Biol103:87-94, 1986
15.
15. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoutos GD. ERKs a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and EGFR. Cell65:663-675, 1991
16.
16. Margolis B, Rhee SG, Felder S, Mervic M, Layall R, Levitski A, Ullrich A, Zilberstein A, Schlessinger J.EGFR induces phosphorylation of phospholipase II-c: A potential mechanism for EGFR signaling. Cell57:1101-1107, 1989
17.
17. Alvarez E, Northwood IC, Gonzalez FH, Latour DH, Seth A, Abate C, Curran T, Davis. Pro-Leu-Ser/Thrpro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor 669 protein kinase. J Biol Chem266:15277-15285, 1991
18.
18. Gille H, Sharrocks AD, Shaw PE. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates terniary complex formation at fos promoter. Nature358:414-417, 1992
19.
19. Seth A, Alvarez E, Gupta S, Davis RJ. A phosphorylation site located in the NH2-terminal domain of cMyc increases transactivation of gene expression. J Biol Chem266:23521-23524, 1991
20.
20. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T.SH2 and DH3 domains: Elements that control interactions of cytoplasmic signaling proteins. Science252:668-674, 1991
21.
21. Ullrich A, Schlessinger J.Signal transduction by receptors with tyrosine kinase activity. Cell61:203-212, 1990
22.
22. Fleming TP, Sazena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res52:4550-4553, 1992
23.
23. Yoshida K, Kyo E, Tsuda T, Tsujin T, Ito M, Nimoto M, Tahara E.EGFR and TGF alpha, the ligands of hyperproduced EGFRR in human esophageal carcinoma cells, acts as autocrine growth factors. Int J Cancer45:131-135, 1990
24.
24. Tahara E.Growth factors and oncogenes in gastrointestinal cancer. J Cancer Res Clin Oncol116:121-131, 1990
25.
25. Sainsbury JRC, Needham GK, Fardon JR, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as a predictor of early recurrence and death from breast cancer. Lancet1: 1398-1402, 1987
26.
26. Pelley RJ, Maihle NJ, Boerkoel C, Shu HK, Carter TH, Moscovici C, Kung HJ. Disease tropism of c-erbB: Effects of carboxyl-terminal tyrosine and internal mutations on tissue specific transformation. Proc Natl Acad Sci USA86:7164-7168, 1989
27.
27. Gamett DC, Tracy SE, Robinson HL. Differences in sequences encoding the carboxyl-terminal domain of the epidermal growth factor receptor correlate with differences in the disease potential of viral erbB genes. Proc Natl Acad Sci USA83:6054-6057, 1986
28.
28. Neal DE, Bennett MK, Hall RR, Marsh CM, Abel PD, Sainsbury JRC, Harris AL. Epidermal growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumors. Lancet1:366-368, 1985
29.
29. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGFR-R) in human breast cancer. A review of 5,232 patients. Endocrine Rev13:3-17, 1992
30.
30. Yasui W, Hata J, Yokozaki H, Nakatani H, Ochiai A, Ito H, Tahara E.Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer41:211-217, 1988
31.
31. Dazzi H, Hasleton PS, Thatcher N, Banes DM, Wilkes S, Swindell R, Lawson RA. Expression of epidermal growth factor receptor (EGFR-R) in nonsmall lung cancer. Use of an archival tissue and correlation of EGFR-R with histology, tumor size, node status and survival. Br J Cancer59:746-749, 1989
32.
32. Rios MA, Perez R, Lage A, Skoog L. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinomas. Anticancer Res8:173-176, 1988
33.
33. de Wit PEJ, Moretti S, Koenders PG, Weterman MAJ, van Muijen GNP, Gianotti B, Ruiter DJ. Increasing epidermal growth factor receptor expression in human melanocytic tumor progressior'Invest Dermatol99:168-173, 1992
34.
34. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al. Tyrosine kinase receptor with extensive homology to EGFR shares chromosomal location with neu oncogene. Science230:1132-1139, 1985
35.
35. Fenoglio-Preiser CM, Longacre TA, Listrom MB. Oncogenes and tumor suppressor genes in breast, gynecologic and urologic tumors. In Fenoglio Preiser CM, Willman CL (eds). Molecular diagnostics in pathology. Williams & Wilkins, Baltimore, pp. 219-260, 1990
36.
36. Slamon DJ,Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science244:707-712, 1989
37.
37. Tiwari RK, Borgen PL, Wong GY, Cordon-Cardo C, Osborne MP. HER2/neu amplification and overexpression in primary breast cancer is associated with early metastasis. Anticancer Res12:419-426, 1992
38.
38. Morson BC, Sobin LH. Histological typing of intestinal tumors. International classification of tumors. World Health Organization, Geneva, 1976
39.
39. Paik S, King CR, Simpson S, Lippman ME. Quantification of erbB-2/neu levels in tissue. Methods Enzymol198:290-300, 1991
40.
40. Lipkin M. Phase 1 and phase 2 proliferative lesions in diseases leading to colon cancer. Cancer34:878-888, 1974
41.
41. Risio M, Lipkin M, Candelaresi GL, Bertone A, Coverlizza S, Rossini FP. Correlations between rectal mucosa cell proliferation and the clinical and pathologic features of nonfamilial neoplasia of the large intestine. Cancer Res51:1917-1921, 1991
42.
42. Wille JJ, Pittelkow MR, Shipley GD, Scott RE. Integrated control of growth and differentiation of normal human prokeratinocytes cultures in serum free medium: Clonal analysis, growth kinetics and cell cycle studies. J Cell Physiol121:31-44, 1984
43.
43. Celis JE, Celis A. Cell cycle dependent variations in the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc Natl Acad Sci USA82:3262-3266, 1985
44.
44. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H.PCNA is an auxiliary protein of DNA polymerase 6. Nature326:515-517, 1987
45.
45. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conversation and the detection of a nucleolar form. J Cell Sci96:121-129, 1990
46.
46. Lee SH, Hurwitz J.Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen, and activator 1. Proc Natl Acad Sci (USA)87:5672-5676, 1990
47.
47. Gelb AB, Kamel OW, LeBrun DP, Warnke RA. Estimation of tumor growth fractions in archival formalin-fixed tissues using two anti-PCNA/cyclin monoclonal antibodies. Factors affecting reactivity. Am J Pathol141:1453-1458, 1992
48.
48. Jaskulski D, deRiel JK, Mercer WE, Calabretta B, Baserga R.Inhibition of cellular proliferation by antisense oligonucleoticles to PCNA cyclin. Science240:1544-1546, 1988
49.
49. Galand P, Degraef C.Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labeling for marking S-phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet22:383-392, 1989
50.
50. Fontanini G, Pingitore R, Bigni D, Vignati S, Pepe S, Ruggiero A, Macchiarini P.Growth factor in nonsrnall cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data. Am J Pathol141:1285-1290, 1991
51.
51. Garcia RL, Coltrera MD, Grown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues: Comparison with flow cytometric analysis. Am J Pathol134:733-739, 1989
52.
52. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol162:285-294, 1990
53.
53. Kern JA, Schwartz DA, Nordberg JE, Wemer DB, Greene MI, Torney L, Robinson RA. pl85neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res50:5184-5187, 1990
54.
54. Volm M, Efferth T, Mattern J.Oncoprotein (c-myc, cerbBl, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinoma of the lung. Clinical and biological correlations. Anticancer Res12:11-20, 1992
55.
55. Rheinwald JG, Green H.Epidermal growth factor and multiplication of cultured human epidermal keratinocytes. Nature265:421-424, 1977
56.
56. Nanney LB, Magid M, Stoscheck CM, King LE. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol83:385-393, 1984
57.
57. Nanney LB, McKanna JA, Stoscheck CM, Carpenter G, King LE. Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol82:165-169, 1984
58.
58. Spaargren M, Defize LHK, Boonstra J, de Laat SW. Antibody-induced dimerization activates the epidermal growth factor receptor. J Cell Physiol266:1733-1739, 1991
60. Goppinger A, Wittmaack FM, Wintzer HO, Ikenberg H, Bauknecht T.Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias. J Cancer Res Clin Oncol115:259-263, 1989
61.
61. Ennis BW, Lippman ME, Dickson RB. The EGFR system as a target for antitumor therapy. Cancer Invest9:553-562, 1991
